KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $42.6 million.

  • Emergent BioSolutions' Other Non-Current Liabilities rose 1899.44% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 1899.44%. This contributed to the annual value of $39.1 million for FY2024, which is 3529.41% up from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Other Non-Current Liabilities is $42.6 million, which was up 1899.44% from $39.5 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Other Non-Current Liabilities registered a high of $69.5 million during Q4 2021, and its lowest value of $23.4 million during Q2 2023.
  • Its 5-year average for Other Non-Current Liabilities is $42.5 million, with a median of $39.5 million in 2025.
  • Per our database at Business Quant, Emergent BioSolutions' Other Non-Current Liabilities crashed by 6000.0% in 2023 and then skyrocketed by 5369.65% in 2025.
  • Over the past 5 years, Emergent BioSolutions' Other Non-Current Liabilities (Quarter) stood at $69.5 million in 2021, then crashed by 40.29% to $41.5 million in 2022, then plummeted by 30.36% to $28.9 million in 2023, then skyrocketed by 35.29% to $39.1 million in 2024, then increased by 8.95% to $42.6 million in 2025.
  • Its Other Non-Current Liabilities was $42.6 million in Q3 2025, compared to $39.5 million in Q2 2025 and $35.4 million in Q1 2025.